UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
September 22, 2005 (September 20, 2005)
Date of Report (Date of earliest event reported)
SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware |
|
000-28782 |
|
93-0979187 |
(State or other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification Number) |
|
|
|
|
|
|
157 Technology Drive
Irvine, California
(Address of principal executive offices)
|
|
|
|
92618
(Zip Code) |
(949) 788-6700
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
1
TABLE OF CONTENTS
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of
Officers.
On September 21, 2005, Spectrum Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that on September 20, 2005,
Richard Fulmer was elected by Company’s Board of Directors (the “Board”) to serve as a Director of the Board, a position created
by the Board's increase in the number of directors from five to six. Mr.
Fulmer will serve on the Board’s Audit, Product Acquisition, and Nominating and Corporate Governance
Committees. Mr. Fulmer’s term expires at our 2006 Annual Meeting of Stockholders. The press
release is attached to this report as Exhibit 99.1 and incorporated herein by reference.
Item 8.01 Other Events.
On September 20, 2005, the Board established, and approved compensation, for the Product Acquisition
Committee of the Board to evaluate the Company’s product acquisition opportunities. Members of the Product Acquisition
Committee will be paid $1,000 for each half day meeting attended and $2,000 for each full day meeting attended. The Board discussed providing Annual
Compensation to the Board’s Lead Director, Dr. Dilip Mehta; However, Dr. Mehta waived his right to receive any additional
compensation for his service in this capacity and requested that the Board only compensate him with an annual retainer of $1, which the Board subsequently
approved. The Summary of Director Compensation is
attached to this report as Exhibit 10.1 and incorporated herein by reference.
(c) Exhibits
| |
|
|
| Exhibits: |
|
Description of Document |
10.1
|
|
Summary of Director Compensation. |
99.1
|
|
Press Release dated September 21, 2005. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 22, 2005
| |
|
|
|
|
| |
SPECTRUM PHARMACEUTICALS, INC.
|
|
| |
By: |
/s/ Shyam Kumaria
|
|
| |
Name: |
Shyam Kumaria |
|
|
| |
Title: |
V.P. Finance |
|
|
| |
2